U.S. markets open in 35 minutes
  • S&P Futures

    3,756.00
    +11.75 (+0.31%)
     
  • Dow Futures

    30,330.00
    +141.00 (+0.47%)
     
  • Nasdaq Futures

    13,079.50
    -26.00 (-0.20%)
     
  • Russell 2000 Futures

    2,128.00
    +23.70 (+1.13%)
     
  • Crude Oil

    53.19
    +0.34 (+0.64%)
     
  • Gold

    1,850.00
    +5.10 (+0.28%)
     
  • Silver

    25.97
    +0.58 (+2.29%)
     
  • EUR/USD

    1.2121
    +0.0010 (+0.08%)
     
  • 10-Yr Bond

    1.0210
    +0.0070 (+0.69%)
     
  • Vix

    32.39
    +9.37 (+40.70%)
     
  • GBP/USD

    1.3674
    -0.0017 (-0.13%)
     
  • USD/JPY

    104.3120
    +0.2400 (+0.23%)
     
  • BTC-USD

    31,932.29
    +1,102.92 (+3.58%)
     
  • CMC Crypto 200

    646.10
    +18.44 (+2.94%)
     
  • FTSE 100

    6,511.96
    -55.41 (-0.84%)
     
  • Nikkei 225

    28,197.42
    -437.79 (-1.53%)
     

Recap: Cantel Medical Q4 Earnings

Benzinga Insights
·1 min read

Shares of Cantel Medical (NYSE:CMD) moved higher by 4.9% in pre-market trading after the company reported Q4 results.

Quarterly Results

Earnings per share fell 61.90% over the past year to $0.24, which beat the estimate of ($0.01).

Revenue of $233,371,000 declined by 2.55% from the same period last year, which beat the estimate of $223,640,000.

Outlook

Cantel Medical hasn't issued any earnings guidance for the time being.

Cantel Medical hasn't issued any revenue guidance for the time being.

Conference Call Details

Date: Sep 17, 2020

View more earnings on CMD

Time: 08:30 AM

ET Webcast URL: https://www.webcaster4.com/Webcast/Page/2203/36688

Recent Stock Performance

52-week high: $90.79

52-week low: $20.81

Price action over last quarter: down 2.17%

Company Description

Cantel Medical is a New Jersey-based manufacturer of hospital supplies for infection prevention, which include products used in endoscope disinfection, water purification systems for use in dialysis treatment, and dental supplies. The firm reports in four segments: medical (57% of fiscal 2019 sales), life sciences (22%), dental (18%), and dialysis (4%). Geographic exposure is primarily in the U.S., which accounts for 75% of revenue, with international markets making up the remaining 25%.

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.